首页    期刊浏览 2024年07月05日 星期五
登录注册

文章基本信息

  • 标题:Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013
  • 本地全文:下载
  • 作者:Srinivas Murthy ; Kenneth D. Mandl ; Florence T. Bourgeois
  • 期刊名称:Health Research Policy and Systems
  • 印刷版ISSN:1478-4505
  • 电子版ISSN:1478-4505
  • 出版年度:2015
  • 卷号:13
  • 期号:1
  • 页码:28
  • DOI:10.1186/s12961-015-0019-6
  • 语种:English
  • 出版社:BioMed Central
  • 摘要:Industry-sponsored clinical trials, in the past performed almost exclusively in more developed countries, now often recruit participants globally. However, recruitment from outside high-income countries may not represent the ultimate target population for the intervention. Clinical trial registries provide an opportunity to quantify and examine the type of clinical research performed in various geographic regions. We sought to characterize industry-sponsored randomized controlled trials conducted in high-income countries and to compare these trials to those performed outside high-income countries. Clinical trial data on all industry-funded randomized controlled trials conducted between 2006 and 2014 were obtained from the registry ClinicalTrials.gov. Trials were classified according to their study sites as conducted in high or non-high income countries, and data on trial characteristics were collected. Of 22,511 relevant trials, a total of 6,085 (27.0 %) trials included study sites outside a high-income country, and 2,045 (9.1 %) were conducted exclusively outside high-income countries. Of country groups, Central Europe had the greatest number of trials (3,127), followed by Eastern Europe (2,075). The percentage of trials with study sites outside high-income countries remained relatively constant over the study period. Studies with sites outside high-income countries tended to recruit more participants (median enrolled participants 265 vs. 71, P <0.001), to be longer (median study duration 20 vs. 13 months, P <0.05), and to study more advanced phase interventions (Phase 3 or 4 trial 58 % vs. 33 %, P <0.001). More than a quarter of industry-sponsored trials include participants from outside high-income countries and this rate remained stable over the 7-year study period. Trials conducted outside high-income countries tend to be larger, have a longer duration, and study later phase interventions compared to studies performed exclusively in high-income countries.
  • 关键词:Clinical trials ; Global health ; Pharmaceutical companies
国家哲学社会科学文献中心版权所有